

ASMS 2019 WP-530

Tiphaine Robin¹, Stéphane Moreau², Franck Saint-Marcoux¹, Etienne Maout³ S1 CBRS, Limoges, France. 2 Shimadzu Europa GmbH, Duisburg, Germany. 3 Shimadzu France, Paris, France.

PO-CON1865E



Overview

• Pre-packed QueChERS salts

• Fast sample extraction

Introduction

Extraction procedures using QuEChERS consist of manually adding salts to the analyzed matrix, previously mixed in a polar solvent (acetonitrile, ACN). This approach is largely employed for pesticides residues but also for multiples classes of drugs.

• In this study, we explored the performance of a QuEChERS extraction based on a **new pre-packed kit containing 100 mg of salts** (Micro Volume QuEChERS; MVQ) and compared it to a previously validated procedure, routinely used in a clinical lab [1].

The example of an LC-MS method for the analysis of 44 Drugs Of Abuse (DOA) using this new device is presented.



Figure 1: Pre-packed QuEChERS salts vs manual procedure



Results

Application to patient samples

The two procedures were applied to 18 real samples (14 urines and 4 oral fluids) from patients tested for DOA consumption.

79 molecules were detected by the two procedures : 6-acetylmorphine (2), amphetamine (1), anhydroecgonine methyl ester (1), benzoylecgonine (12), cocaethylene (4), cocaine (9), dihydrocodeine (3), EDDP (4), ecgonine methylester (11), hydrocodone (2), hydromorphone (4), MDA (3), MDMA (4), methadone (4), methamphetamine (1), methylmorphine (5),morphine (7), norbuprenorphine (2).

A regression analysis for concentrations measured from 3 to 500 μ g/L (LOQ and ULOQ of the method, respectively) reported a R² greater than 0.98.





Application to Internal quality controls (IQC)

Repeatability (n=6) was explored using 2 different whole blood IQC containing **16 molecules** at **low concentration** (QC A) and **intermediate concentration** (QC B). Similar CV and accuracy were obtained for the 2 procedures.

		Reference interval	Manual Extraction		Pre-packed QuEChERS	
			CV	Accuracy	CV	Accuracy
Amphetamine	QC A	18.88 - 28.32	5.0	107.8	1.8	93.0
	QC B	55.52 - 83.28	5.2	104.5	3.1	91.9
Methamphetamine	QC A	19.04 - 28.56	2.9	111.7	2.4	93.6
	QC B	56.80 - 85.20	2.6	109.4	2.8	92.9
MDA	QC A	18.32 - 27.48	12.0	113.4	3.2	99.9
	QC B	56.00 - 84.00	4.7	106.1	3.5	91.0
MDEA	QC A	18.88 - 28.32	5.0	108.7	2.6	89.2
	QC B	55.76 - 83.64	2.8	105.2	2.8	87.0
MDMA	QC A	19.44 - 29.16	2.5	116.8	2.5	96.4
	QC B	55.76 - 83.64	0.9	116.4	1.8	93.3
Mephedrone	QC A	16.96 - 25.44	9.7	99.1	3.0	74.8
	QC B	46.24 - 69.36	6.6	99.9	2.7	75.7
Cocaine	QC A	11.68 - 17.52	1.6	102.1	1.4	95.0
	QC B	59.96 - 85.44	2.6	103.4	3.0	90.7
Benzoylecgonine	QC A	22.88 - 34.32	2.1	124.3	2.6	98.8
	QC B	93.60 - 140.40	2.4	118.0	3.6	95.0
Ecgoninmethylester	QC A	12.72 - 19.08	3.0	122.9	5.5	100.7
	QC B	45.60 - 68.40	1.8	121.4	3.1	96.6
Cocaethylene	QC A	10.72 - 16.08	1.6	104.4	2.8	98.7
	QC B	52.72 - 79.08	1.7	102.2	3.0	92.3
Morphine	QC A	7.76 - 11.64	9.8	139.4	5.2	100.7
	QC B	56.32 - 84.48	2.5	115.6	8.6	87.8
Codeine	QC A	7.52 - 11.28	4.2	113.0	10.9	97.3
	QC B	53.12 - 79.68	2.6	115.4	4.5	96.8
Dihydrocodeine	QC A	19.2 - 28.8	3.7	107.6	4.8	95.1
	QC B	54.00 - 81.00	2.5	110.5	3.9	95.2
6-MAM	QC A	8.08 - 12.12	6.6	118.6	4.1	91.9
	QC B	30.48 - 45.72	6.1	137.0	4.0	89.4
Oxycodone	QC A	16.56 - 24.84	3.0	100.1	2.7	96.7
	QC B	57.28 - 85.92	0.9	102.2	3.9	90.0
Pholcodine	QC A	17.44 - 26.16	15.5	123.4	3.1	97.3
	QC B	50.32 - 75.48	9.0	128.0	4.4	90.5
Min-Max CV			0.9 -15.5		1.4 -10.9	
Mean accuracy				112.8		93.0

Table 1: Repeatability study for the two procedures



Conclusion

• Using the example of the preparation of samples for measurements of DOA, this preliminary study suggests that the MVQ kit has the same performance as the manual sample preparations based on QuEChERS salts. It avoids weighing the salts and having to put them into tubes, which obviously shortens the time required for extraction and reduces possible human errors.

Reference

1. Dulaurent S et al. Anal Bioanal Chem 2016

Disclaimer: For Research Use Only. Not for use in diagnostic procedures. This presentation may contain references to products that are not available in your country. All rights reserved. Information subject to change without notice.



Shimadzu Corporation

www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "@".

Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®".

Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.